Perrigo rejects Mylan, opening door for Teva - MarketWatch
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva: Avoid (NYSE:TEVA) | Seeking Alpha
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
Teva Pharmaceutical Is in Recovery - WSJ
Drugmaker Teva Pharmaceuticals found guilty for contribution to opioid crisis - MarketWatch
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
Teva Appoints New Chief Executive After Months of Speculation - WSJ
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Is Teva A Falling Drug Company Or A Great Value Proposition (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Generic-drug stocks slammed by report of expanded price-fixing probe - MarketWatch
FDA approves first rival generic EpiPen, sending Teva shares up 6% - MarketWatch
Teva Pharmaceuticals - Wikipedia
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
Is the new Teva x Ugg collection fashion-forward or just plain ugly? - MarketWatch
